Kamada Strengthens Plasma Supply Business with $50M Deal
REHOVOT, Israel, and HOBOKEN, NJ | July 20, 2026 Kamada Ltd. announced a three-year plasma supply agreement valued at...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
REHOVOT, Israel, and HOBOKEN, NJ | July 20, 2026 Kamada Ltd. announced a three-year plasma supply agreement valued at...
September 29, 2025 – Kedrion Biopharma announced a major regulatory and strategic milestone with the U.S. Food and Drug...
